Compass to submit psilocybin depression drug for approval imminently after stock wobbles - BioSpace
BioSpace · Nov 3, 4:30 PM
Earnings call transcript: COMPASS Pathways beats Q3 2026 loss estimate - Investing.com
Investing.com · Nov 3, 2:04 PM
Market reactionShares fell 27% on Nov 2.
COMPASS Pathways is a clinical-stage company developing COMP360, a psilocybin treatment given under supervision, for treatment-resistant depression and PTSD; it is not approved.
Compass's case rests on COMP360 for treatment-resistant depression, where two Phase 3 trials met their primary endpoints. The final rolling NDA submission is expected within two weeks; the National Priority Voucher could shorten review to 1-2 months. Launch in the first half of 2027 requires FDA approval and DEA rescheduling. Cash of $444.0 million is expected to fund operations into 2028. A late-stage PTSD trial offers additional potential, while COMP005 open-label follow-up supports durability with additional dosing.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The rolling NDA is completed in Q4 2026
Does Compass complete the final NDA submission on its stated timetable?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
COMP360 final NDA submission expected within two weeks; approval and rescheduling remain ahead
Two Phase 3 wins and a CNPV in hand; COMP360's TRD approval bid now rests on FDA's approvability verdict on psychedelic-assisted therapy
COMP360's Phase 3 TRD win sets up a first-in-class psilocybin NDA; FDA approval and commercial execution are the remaining tests
COMP005 and COMP006 Phase 3 primary endpoints met at Week 6
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
3 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.